Studies have demonstrated that XBP1-mediated expression of T-cell-suppressive checkpoints in myeloid cells, such as PD1, prevents the activation of tumour infiltrating T cells in GBM, thereby leading to resistance to anti-PD1 therapy [166]. Here, PDCD1 is linked to glioblastoma.